Oracle Investment Management Inc buys $69,831,047 stake in NxStage Medical (NXTM)

NxStage Medical (NXTM) : Oracle Investment Management Inc scooped up 1,400 additional shares in NxStage Medical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 2,671,936 shares of NxStage Medical which is valued at $69,831,047.NxStage Medical makes up approximately 10.27% of Oracle Investment Management Inc’s portfolio.

Other Hedge Funds, Including , Parametric Portfolio Associates reduced its stake in NXTM by selling 13,140 shares or 28.63% in the most recent quarter. The Hedge Fund company now holds 32,753 shares of NXTM which is valued at $856,000. Bessemer Group Inc added NXTM to its portfolio by purchasing 16,800 company shares during the most recent quarter which is valued at $429,912.Geode Capital Management boosted its stake in NXTM in the latest quarter, The investment management firm added 28,243 additional shares and now holds a total of 489,623 shares of NxStage Medical which is valued at $12,529,453. NxStage Medical makes up approx 0.01% of Geode Capital Management’s portfolio.Rhumbline Advisers boosted its stake in NXTM in the latest quarter, The investment management firm added 1,385 additional shares and now holds a total of 71,591 shares of NxStage Medical which is valued at $1,760,423.

NxStage Medical opened for trading at $26.28 and hit $26.61 on the upside on Monday, eventually ending the session at $26.3, with a gain of 0.61% or 0.16 points. The heightened volatility saw the trading volume jump to 2,43,184 shares. Company has a market cap of $1,703 M.

On the company’s financial health, NxStage Medical reported $-0.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.04. The company had revenue of $92.20 million for the quarter, compared to analysts expectations of $89.30 million. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.08 EPS.

NxStage Medical Inc. is a medical device company. The Company is engaged in the development manufacturing and marketing of products for the treatment of kidney failure fluid overload and related blood treatments and procedures. The Company’s products include the System One Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product the System One is a small portable easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller portable easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One In-Center and Services.

Leave a Reply

NxStage Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on NxStage Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.